Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02682511 · ClinicalTrials.gov registry record · Phase 2

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

A Phase 2 study of Autoimmune Diseases and Skin Diseases, sponsored by Cumberland Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
34
Enrollment target
13
Study locations

NCT02682511 is a Phase 2 study of Autoimmune Diseases and Skin Diseases that is active but no longer recruiting, run by Cumberland Pharmaceuticals. The registered enrollment target is 34 participants, below the 977-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02682511, a Phase 2 study of Autoimmune Diseases and Skin Diseases, is active but no longer recruiting, sponsored by Cumberland Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

Conditions Studied

Autoimmune Diseases Skin Diseases Pathologic Processes Scleroderma, Systemic Connective Tissue Diseases Scleroderma, Diffuse Scleroderma, Limited Sclerosis, Progressive Systemic

Interventions

  • DRUG Oral Placebo
  • DRUG Oral Ifetroban

Study Locations (13)

Maharashtra

  • KDH - Kokilaben Dhirubhai Ambani Hospital - Mumbai
  • B. J. Government Medical College - Pune

Arizona

  • The Universtity of Arizona Arthrtis Center - Tucson

California

  • UCLA - Los Angeles

Florida

  • Cleveland Clinic - Florida - Weston

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Nebraska

  • University of Nebraska Medical Center - Omaha

New York

  • Hospital for Special Surgery - New York

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2017-01
Est. Completion 2026-05
Phase Phase 2

Sponsor

Cumberland Pharmaceuticals

43 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02682511

The ClinicalTrials.gov registry entry for NCT02682511 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 977-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (97% lower). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 2 interventions - of which Oral Placebo is the first listed.

NCT02682511 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Maharashtra, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT02682511 about?

NCT02682511 is a clinical study titled "Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension". The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

What is the current status of trial NCT02682511?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-01. Estimated completion is 2026-05.

What conditions does trial NCT02682511 study?

This clinical trial studies the following conditions: Autoimmune Diseases, Skin Diseases, Pathologic Processes, Scleroderma, Systemic, Connective Tissue Diseases.

What interventions are being tested in trial NCT02682511?

The interventions under investigation include: Oral Placebo (DRUG), Oral Ifetroban (DRUG).

Who is sponsoring clinical trial NCT02682511?

This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02682511 being conducted?

This trial has 13 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autoimmune Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Autoimmune Diseases

All registered trials for this condition

Skin Diseases

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.